Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects.
复制标题
矿物皮质受体拮抗剂对肥胖受试者中胰岛素抵抗和内皮功能的影响。
DOI：
10.1111/dom.12224
复制
发表时间：
2014-03
期刊：
影响因子：
--
通讯作者：
Adler GK
中科院分区：
文献类型：
--
作者：
Garg R;Kneen L;Williams GH;Adler GK
Obese individuals have high aldosterone levels that may contribute to insulin resistance (IR) and endothelial dysfunction leading to obesity induced cardiovascular disease. We conducted a study to evaluate the effect of mineralocorticoid receptor antagonism on IR and endothelial function in obese individuals. This was a placebo-controlled, double blind, randomized, parallel-group study (NCT01406015). Thirty two non-diabetic, obese subjects (BMI 30 to 45 kg/m2) with no other medical problems were randomized to six weeks of treatment with spironolactone 50 mg daily or placebo. Insulin sensitivity index (ISI) was assessed by Matsuda method, endothelial function by flow mediated vasodilatation (FMD) of brachial artery and renal plasma perfusion by clearance of para-aminohippurate (PAH). There was no change in weight, BMI or plasma potassium during the study period. Treatment with spironolactone led to increases in serum aldosterone (7.6±6.6 Vs 3.2±1.3 ng/dL; p <0.02, post-treatment Vs baseline) and urine aldosterone (11.0±7. Vs 4.8±2.4 µg/G creatinine; p<0.01) and decreases in systolic blood pressure (116±11 Vs 123±10 mmHg; p<0.001). There were no changes in these variables in the placebo group. Neither spironolactone nor placebo treatment had a significant effect on ISI or other indices of glucose metabolism (HOMA, area under the curve for insulin, area under the curve for glucose), brachial artery reactivity or the renal plasma perfusion values. Changes in these variables were similar in two groups. We conclude that six weeks of treatment with spironolactone does not change insulin sensitivity or endothelial function in normotensive obese individuals with no other comorbidities.
登录
查看更多内容
影响因子：
120.7
作者：
Hedley, AA;Ogden, CL;Flegal, KM
通讯作者：
Flegal, KM
影响因子：
4.8
作者：
Wada, Tsutomu;Ohshima, Satoshi;Sasaoka, Toshiyasu
通讯作者：
Sasaoka, Toshiyasu
影响因子：
1.2
作者：
Homma, Tsuyoshi;Fujisawa, Michio;Ikeda, Masahiro
通讯作者：
Ikeda, Masahiro
影响因子：
5.8
作者：
Joffe, Hylton V.;Kwong, Raymond Y.;Adler, Gail K.
通讯作者：
Adler, Gail K.
影响因子：
1.8
作者：
Radikova, Z.;Koska, J.;Klimes, I.
通讯作者：
Klimes, I.